Profitability Metrics

Gross Margin
51.89%
Operating Margin
7.94%
Net Margin
-13.24%

Efficiency Metrics

Revenue per Expense Ratio
1.06
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
40.20%
Income Tax Rate
-29,600,000.0%
EPS
-0.7800000000

Balance Sheet Analysis

Current Ratio
2.30
Cash Ratio
0.88
Working Capital
$242.61M
Debt to Equity
1.19
Debt to Assets
47.80%
Equity Ratio
40.28%

Cash Flow Analysis

Operating Cash Flow Ratio
30.35%
Free Cash Flow Ratio
-24.89%
CapEx to Revenue
55.24%
Dividends Paid
$94.00M
Stock Buybacks
$335.31M
Total Shareholder Returns
$429.32M
Cash Position Change
-26.87%

Key Takeaways (2023 FY)

  • Revenue declined by 0.26839478132263%, indicating potential market challenges

Detailed Growth Metrics

Core Performance

Revenue
-0.27%
Net Income
-193.68%
EPS
-211.43%
Operating Income
47.08%

Operational Efficiency

R&D Expenses
-100.00%
SG&A Expenses
-13.01%
Operating Cash Flow
3.00%
Free Cash Flow
-1.12%

Balance Sheet Health

Assets
-6.52%
Debt
8.23%
Book Value per Share
-4.58%
Inventory
100.00%

Shareholder Returns

Dividends per Share
-1.16%
Shares Outstanding
-11.69%

Long Term Trends

3Y Revenue/Share
27.29%
5Y Revenue/Share
6.36%
3Y Dividend/Share
-0.54%
5Y Dividend/Share
-0.72%